PURPOSE: As hypoxia is believed to play an important role in the development and progression of prostate cancer, we evaluated whether 18F-labeled fluoroazomycin arabinoside (18F-FAZA) would be useful to identify tumor hypoxia in resectable prostate cancer. METHODS: Positron emission tomography (PET)/CT was performed on 14 patients with untreated localized primary prostate cancer 3 h post-injection of approximately 390 MBq of 18F-FAZA using forced diuresis to decrease radioactivity in the urinary bladder. Anatomical trans-pelvic coil and pre- and post-contrast 1.5 T MRI with endorectal coil were performed on the same day. Patients underwent radical prostatectomy and ex vivo 3 T MRI of the prostatectomy specimen within 14 days following in vivo imaging. Imaging results were verified by whole mount histopathology plus tissue microarray (TMA) immunohistochemical (IHC) analysis for carbonic anhydrase IX (CAIX) and hypoxia-inducible factor 1α (HIF-1α). Registration of in vivo imaging with histology was achieved using mutual information software and performing ex vivo MRI of the prostatectomy specimen and whole mount sectioning with block face photography as intermediate steps. RESULTS: Whole mount histology identified 43 tumor nodules, 19 of them larger than 1 ml as determined on coregistered volumes featuring 18F-FAZA, MRI, and histological 3-D image information. None of these lesions was found to be positive for CAIX or visualized by 18F-FAZA PET/CT while IHC for HIF-1α showed variable staining of tumor tissues. Accordingly, no correlation was found between 18F-FAZA uptake and Gleason scores. CONCLUSION: Our data based on 18F-FAZA PET/CT and CAIX IHC do not support the presence of clinically relevant hypoxia in localized primary prostate cancer including high-grade disease. Activation of HIF-1α may be independent of tissue hypoxia in primary prostate cancer.
PURPOSE: As hypoxia is believed to play an important role in the development and progression of prostate cancer, we evaluated whether 18F-labeled fluoroazomycin arabinoside (18F-FAZA) would be useful to identify tumor hypoxia in resectable prostate cancer. METHODS: Positron emission tomography (PET)/CT was performed on 14 patients with untreated localized primary prostate cancer 3 h post-injection of approximately 390 MBq of 18F-FAZA using forced diuresis to decrease radioactivity in the urinary bladder. Anatomical trans-pelvic coil and pre- and post-contrast 1.5 T MRI with endorectal coil were performed on the same day. Patients underwent radical prostatectomy and ex vivo 3 T MRI of the prostatectomy specimen within 14 days following in vivo imaging. Imaging results were verified by whole mount histopathology plus tissue microarray (TMA) immunohistochemical (IHC) analysis for carbonic anhydrase IX (CAIX) and hypoxia-inducible factor 1α (HIF-1α). Registration of in vivo imaging with histology was achieved using mutual information software and performing ex vivo MRI of the prostatectomy specimen and whole mount sectioning with block face photography as intermediate steps. RESULTS: Whole mount histology identified 43 tumor nodules, 19 of them larger than 1 ml as determined on coregistered volumes featuring 18F-FAZA, MRI, and histological 3-D image information. None of these lesions was found to be positive for CAIX or visualized by 18F-FAZA PET/CT while IHC for HIF-1α showed variable staining of tumor tissues. Accordingly, no correlation was found between 18F-FAZA uptake and Gleason scores. CONCLUSION: Our data based on 18F-FAZA PET/CT and CAIX IHC do not support the presence of clinically relevant hypoxia in localized primary prostate cancer including high-grade disease. Activation of HIF-1α may be independent of tissue hypoxia in primary prostate cancer.
Authors: Jonathan J Ord; Sachin Agrawal; Thomas P Thamboo; Ian Roberts; Leticia Campo; Helen Turley; Cheng Han; Derek W Fawcett; Ravi P Kulkarni; David Cranston; Adrian L Harris Journal: J Urol Date: 2007-06-15 Impact factor: 7.450
Authors: Roy Vergis; Catherine M Corbishley; Andrew R Norman; Jaclyn Bartlett; Sameer Jhavar; Michael Borre; Sara Heeboll; Alan Horwich; Robert Huddart; Vincent Khoo; Ros Eeles; Colin Cooper; Matthew Sydes; David Dearnaley; Chris Parker Journal: Lancet Oncol Date: 2008-03-17 Impact factor: 41.316
Authors: Ambros J Beer; Anca-Ligia Grosu; Janette Carlsen; Andreas Kolk; Mario Sarbia; Isabelle Stangier; Petra Watzlowik; Hans-Jürgen Wester; Roland Haubner; Markus Schwaiger Journal: Clin Cancer Res Date: 2007-11-15 Impact factor: 12.531
Authors: Subhash S John; Anthony L Zietman; William U Shipley; Mukesh G Harisinghani Journal: Int J Radiat Oncol Biol Phys Date: 2008 Impact factor: 7.038
Authors: Roswitha Beck; Barbara Röper; Janette Maria Carlsen; Marc Cornelis Huisman; Julia Aloisia Lebschi; Nicolaus Andratschke; Maria Picchio; Michael Souvatzoglou; Hans-Jürgen Machulla; Morand Piert Journal: J Nucl Med Date: 2007-06 Impact factor: 10.057
Authors: M Souvatzoglou; A L Grosu; B Röper; B J Krause; R Beck; G Reischl; M Picchio; H-J Machulla; H-J Wester; M Piert Journal: Eur J Nucl Med Mol Imaging Date: 2007-04-20 Impact factor: 9.236
Authors: Weranja K B Ranasinghe; Graham S Baldwin; Arthur Shulkes; Damien Bolton; Oneel Patel Journal: Nat Rev Urol Date: 2014-07-01 Impact factor: 14.432
Authors: Eline E Verwer; Floris H P van Velden; Idris Bahce; Maqsood Yaqub; Robert C Schuit; Albert D Windhorst; Pieter Raijmakers; Adriaan A Lammertsma; Egbert F Smit; Ronald Boellaard Journal: Eur J Nucl Med Mol Imaging Date: 2013-06-06 Impact factor: 9.236
Authors: Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb Journal: Antioxid Redox Signal Date: 2014-05-09 Impact factor: 8.401